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Abstract
The s-2 receptor (S2R) complex has been implicated in CNS disorders ranging from anxiety and depression
to neurodegenerative disorders such as Alzheimer’s disease (AD). The proteins comprising the S2R complex
impact processes including autophagy, cholesterol synthesis, progesterone signaling, lipid membrane-bound
protein trafficking, and receptor stabilization at the cell surface. While there has been much progress in under-
standing the role of S2R in cellular processes and its potential therapeutic value, a great deal remains un-
known. The International Symposium on Sigma-2 Receptors is held in conjunction with the annual Society for
Neuroscience (SfN) conference to promote collaboration and advance the field of S2R research. This review
summarizes updates presented at the Fourth International Symposium on Sigma-2 Receptors: Role in Health
and Disease, a Satellite Symposium held at the 2019 SfN conference. Interdisciplinary members of the S2R re-
search community presented both previously published and preliminary results from ongoing studies of the
role of S2R in cellular metabolism, the anatomic and cellular expression patterns of S2R, the relationship be-
tween S2R and amyloid b (Ab ) in AD, the role of S2R complex protein PGRMC1 in health and disease, and
the efforts to design new S2R ligands for the purposes of research and drug development. The proceedings
from this symposium are reported here as an update on the field of S2R research, as well as to highlight the
value of the symposia that occur yearly in conjunction with the SfN conference.
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Introduction
The s receptors were first identified in the 1970s and
were initially believed to be opioid receptors because of
the CNS effects of their ligand SKF10047; they were rec-
ognized as distinct when opiate antagonists were found
not to block their activity (Martin et al., 1976). The s-2
receptor (S2R) was recognized apart from s-1 (S1R) in
the early 1990s (Hellewell and Bowen, 1990). Since then,
s receptors have continued to be of interest in the field of
neuroscience because of effects in schizophrenia, de-
pression and anxiety, pain, and neuroprotection (for
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review of s receptor history and nomenclature, see Zeng
and Mach, 2017). Despite the broad potential relevance of
S2Rs to the treatment of these neurologic conditions, no
selective S2R compound has yet achieved clinical suc-
cess. The absence of an identified protein corresponding
to S2R hampered progress toward understanding its role
in the brain for many years. In 2011, the S2R complex was
found to contain the PGRMC1 protein complex (Xu et al.,
2011). This discovery expanded the field of S2R research
to include the effects of PGRMC1, among which are im-
pacts on oxic/glycolytic and sterol metabolism, mem-
brane trafficking, growth factor release, axon guidance in
neurodevelopment, and neuroprotection (Su et al., 2012;
Kabe et al., 2016; Nicholson et al., 2016; Cahill, 2017;
Cahill and Medlock, 2017).
Studies of this complex accelerated with the identifica-
tion of TMEM97 as a gene coding for S2R activity in
tumor cell lines in 2017 (Alon et al., 2017). In the following,
we refer to undefined S2R ligand binding activity as S2R
and functions known to involve TMEM97 as S2R/
TMEM97. S2R/TMEM97 has now been shown to play a
role in cellular damage response mechanisms, and its
constituent proteins regulate processes, including au-
tophagy, cholesterol synthesis and progesterone signal-
ing, lipid membrane-bound protein trafficking, and
receptor stabilization at the cell surface (Cahill, 2007;
Ahmed et al., 2012; Su et al., 2012; Cahill et al., 2016;
Nguyen et al., 2018; Riad et al., 2018; Oyer et al., 2019).
Additional binding partners for S2R/TMEM97 have been
determined, notably the low-density lipoprotein receptor
(LDLR), an interaction that has implications for lipid home-
ostasis and Alzheimer’s disease (AD; Riad et al., 2018).
Furthermore, S2R/TMEM97 has most recently been iden-
tified as a binding partner for SARS-CoV-2, the novel co-
ronavirus, as it interacts with the viral protein orf9c, while
the S1R interacts with Nsp6 (Gordon et al., 2020).
Despite the progress that has been made in the under-
standing of the importance of S2R and its receptor com-
plex proteins in cellular processes and its potential value
as a therapeutic target in a variety of diseases, a great
deal remains unknown. For instance, some S2R ligand
activity is independent of TMEM97 (Zeng et al., 2019).
Notably, there are few selective S2R small molecule ago-
nist and antagonists that are widely available for research
purposes, and the relationship between S2R, TMEM97,
PGRMC1, and other binding partners is still coming into
focus.
In an effort to promote collaboration and collective
understanding of this receptor complex, the International
Symposium on Sigma-2 Receptors is held in conjunction
with the annual Society for Neuroscience (SfN) confer-
ence. Here, we summarize both published and preliminary
updates to the field of S2R research that were presented
at the Fourth International Symposium on Sigma-2
Receptors: Role in Health and Disease, a SfN Satellite
Symposium, held in October 2019. Results presented at
the symposium that have not since been published in the
peer reviewed literature are not discussed here or are indi-
cated as preliminary.
Metabolic Effects of S2R Ligands
S2R agonists have traditionally been characterized as
ligands that induce programmed cell death in various cell
types through a number of mechanisms (Crawford and
Bowen, 2002; Zeng et al., 2012). Despite this pharmaco-
logical profile, a recent study showed that knock-out of
TMEM97 did not affect the cytotoxic potency of some
S2R ligands, casting doubt on the role of S2R/TMEM97 in
previously established cytotoxic effects, and implying the
existence of yet unidentified S2R activities (Zeng et al.,
2019). Bowen and colleagues have identified analogs of
the canonical S2R antagonist SN79. Some of these are
able to induce apoptotic cell death, while others display a
novel metabolically stimulative effect (Nicholson et al.,
2015, 2016, 2019). This metabolic effect is characterized
by increased reductive capacity as indicated by stimula-
tion of MTT [3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetra-
zolium bromide] reduction, increase in cellular ATP
(Adenosine triphosphate) level, reduction in basal ROS
(Reactive Oxygen Species) level, and stabilization of HIF-
1a, as determined in human SK-N-SH neuroblastoma
cells (Nicholson et al., 2016). Bowen presented ongoing
research at the 2019 SfN meeting and at this S2R satellite
symposium that further characterizes this prometabolic
effect using additional analogs of SN79 (McVeigh et al.,
2019). Preliminary findings suggest that CM764, CM571,
and WA504 (S2R Ki = 3.5, 21.7, and 2.5 nM, respectively)
induced dose-dependent stimulation of MTT reduction by
45%, 33%, and 75%, respectively, at the highest dose
examined (30 mM) after a 24-h treatment. Analogs lacking
S2R affinity and structural fragments of the active com-
pounds appear not to have this effect. An examination of
the time course suggests that it may take 3–6 h of treat-
ment for this stimulative effect to fully develop. These pre-
liminary findings were consistent with the time course for
HIF-1a stabilization shown previously (Nicholson et al.,
2016). Like some other S2R ligands (Vilner and Bowen,
2000), all three compounds appear to induce a transient
and dose-dependent (10 and 30 mM) increase in cytosolic
calcium, an effect that was blocked by thapsigargin pre-
treatment (150 nM), suggesting that the calcium release is
derived from stores within the endoplasmic reticulum
(ER). Based on evidence that calcium signaling plays a
role in inducing expression of HIF-1a, a global regulator
of the glycolytic pathway (Li et al., 2012; Divolis et al.,
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2016), it is possible that the S2R ligands described here
impact glycolysis through ER calcium release, a down-
stream upregulation of HIF-1a, and a resulting upregulation
of glycolytic pathways that may have neuroprotective impli-
cations such as protection against oxidative and hypoxic
stress. If these preliminary findings are confirmed through
further ongoing studies, the results may suggest that S2R
plays a role in adaptation of cancer tumor cells to hypoxic
environments by upregulating Warburg glycolysis. This ef-
fect would be consistent with S2R upregulation in cancer
cells. However, whether TMEM97 or another related protein
with similar pharmacology mediates these effects is still
under investigation.
Expression and Localization of S2R in the
Brain
Appreciating the localization of the s receptors in the
human brain is important to understanding their role in
health and disease. To this end, Xu and colleagues have
performed quantitative autoradiography on postmortem
samples. N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2
(1H)-yl)butyl]2-methoxy-5-methyl-benzamide (RHM-1)
has high affinity and selectivity for the S2R (Ki, 10 nM)
compared with the S1R (ratio. 300; Mach et al., 2004; Xu
et al., 2005). Radiolabeled RHM-1 was therefore used to
assess the distribution and expression of S2Rs across
human brain samples, and Xu presented preliminary find-
ings from these experiments at the S2R symposium.
These findings suggest that both the S1R and S2R are ex-
tensively distributed across brain regions, and that S2R
may be more highly expressed than the S1R in all brain re-
gions (frontal cortex, precommissural caudate and puta-
men, postcommissural caudate and putamen, nucleus
accumbens, globus pallidus, thalamus, and substantial
nigra) except the red nucleus, where expression levels of
the two were comparable and lower than in the other re-
gions assessed.
Expression of S2R appears from these experiments to
be higher in aged brains, a finding that prompted the
question of whether S2R plays a role in disorders such as
AD and Parkinson’s disease (PD). The authors therefore
are also comparing S1R and S2R expression patterns
with those of Tau using the selective Tau radioligand [3H]
MK6240 in frontal cortex. Preliminary results from aged
AD brains (N=7; six females and one male; aged 74–
88 years, Tau tangle rating: 4–6) do not suggest an ob-
vious correlation between Tau density and either S1R or
S2R expression, but research is still ongoing.
Although these radioligand studies have thus far not re-
vealed a correlation between Tau expression and S2R ac-
tivity, the laboratory of Spires-Jones is further assessing
the subcellular localization of TMEM97 to determine
whether it is present at synapses or in close proximity to
amyloid b (Ab ) in human AD brain (Hesse et al., 2019). At
the S2R symposium, Colom-Cadena of the Spires-Jones
laboratory presented preliminary findings, which have
since been published, that synaptic fractions that had
been biochemically isolated from human temporal cortex
contained TMEM97 (Hesse et al., 2019). Furthermore, the
presence of TMEM97 in these fractions appears to be
higher in samples isolated from AD patient brain (n=7)
compared with those from healthy controls (n=7), a result
that is supported by preliminary analyses of temporal cor-
tex synapses with high-resolution array tomography;
these suggest that TMEM97 is present at both presynap-
tic and postsynaptic terminals, and in a larger proportion
of synapses in AD (n=9) than in control (n=6) brains.
The authors are furthermore using Förster Resonance
Energy Transfer (FRET) to visualize colocalization of
TMEM97 and Ab . Initial findings from these experiments
suggest the two are in close enough proximity in synap-
ses to generate a FRET signal. If continued investigation
confirms these preliminary findings, TMEM97 may be in-
volved in the mediation of Ab -induced toxicity in AD.
The S2R Complex and Ab
The relationship between S2R/TMEM97 and Ab has
been the subject of many recent studies. S2R/TMEM97
has been shown to form a complex with a number of
other proteins, including PGRMC1 and LDLR (Riad et al.,
2018). This intact trimeric complex is required for efficient
uptake of lipoproteins such as LDL and apolipoprotein E
(ApoE). The TMEM97-PGRMC1-LDLR trimeric complex
was identified in HeLa cells, in primary rat neurons, and in
human brain tissue. The ApoE4 isoform is the greatest
risk factor associated with developing AD, and ApoE is
known to influence the uptake and accumulation of Ab , a
process that eventually leads to synaptic dysfunction and
neurodegeneration in AD. Because of this, the laboratory
of Mach seeks to determine whether the S2R/TMEM97
complex is necessary for internalization of Ab and
whether disruption of the complex inhibits Ab uptake.
To this end, Riad of the Mach laboratory presented re-
sults, since published, from CRISPR/Cas9 knock-out of
TMEM97 or/and PGRMC1 in HeLa cells, as well as the
use of small molecule inhibitors of TMEM97 and
PGRMC1 in primary rat cortical neurons. Uptake of Ab 42
(monomeric or oligomeric) in the presence or absence of
the main ApoE isoforms (ApoE2, ApoE3, and ApoE4) was
assessed using ELISA and confocal microscopy. Uptake
of Ab 42, ApoE, and the Ab 42/ApoE complex was found
to decrease following loss or pharmacological disruption
of TMEM97 or PGRMC1 (Riad et al., 2020). The results
suggest that the S2R/TMEM97 complex is a binding site
for Ab 42 on cell bodies and is critical for its cellular up-
take of Ab 42 and ApoE. Furthermore, the complex may
be a novel pharmacological target for inhibiting Ab 42
neuronal internalization, accumulation, and neurodegen-
eration and therefore suggests an approach to the treat-
ment of AD. Astrocytes and glial cells also facilitate Ab
clearance through lysosomal degradation, although
TMEM97 and PGRMC1 ligands bind more prominently
and with higher affinity in neurons than in glia and the ef-
fect of S2R ligands on clearance from the brain through
uptake by astrocytes and glial is unknown. It remains to
be determined whether S2R inhibitors can be targeted
exclusively toward the neuronal cell population in vivo,
inhibiting neuron-specific Ab uptake, accumulation, and
neurodegeneration.
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Substantial additional evidence for the role of S2R/
TMEM97 in Ab and AD comes from preclinical and clini-
cal biomarker studies of the selective S2R allosteric an-
tagonist CT1812. CT1812 is currently in clinical trials as a
disease-modifying treatment for AD. Previously published
literature indicates that Ab oligomers bind to a multipro-
tein receptor complex composed of the proteins LilRB2,
cellular prion protein, and NogoR (Kim et al., 2013; Smith
et al., 2019) causing synaptotoxicity and cellular damage
followed by cognitive decline in AD. Catalano, Izzo, and
colleagues presented findings at the SfN meeting and at
the S2R satellite symposium that are under peer review
for journal publication at the time the present report was
written (Catalano et al., 2019; Izzo et al., 2019). The find-
ings suggest that the S2R receptor complex regulates the
oligomer receptor complex on neurons. The binding of
CT1812 to S2R likely modulates the conformation of S2R,
which in turn allosterically alters the conformation of the
oligomer binding pocket on oligomer receptors. Binding
pocket destabilization leads to displacement of Ab
oligomers from neurons. Once displaced, Ab oligomers
are unable to rebind as long as threshold concentrations
of CT1812 are present, as demonstrated in binding stud-
ies on neurons in vitro, in hippocampus of living AD trans-
genic mice in vivo, and in AD patient frozen postmortem
neocortical brain tissue sections ex vivo. Consistent with
previously published studies of closely related com-
pounds (Izzo et al., 2014a,b), this effect on Ab oligomers
leads to synaptic restoration in vitro and improved per-
formance in cognitive tasks in rodent AD models.
Results currently under peer review from a phase 1a/2b
clinical trial of CT1812 in mild-to-moderate AD patients
(N=19; MMSE 18–26) were reported (ClinicalTrials.gov
identifier: NCT02907567). Participants received one of
three doses of CT1812 or placebo once daily for 28 d.
Plasma and CSF were collected at baseline and follow-
ing final dose administration, and protein, lipid, and me-
tabolite values were measured using ELISA or tandem
mass spectrometry. CSF concentrations of Ab oligom-
ers were found to be significantly increased in CT1812-
treated patients compared with placebo-treated pa-
tients. This increase is consistent with preclinical studies
demonstrating that CT1812 destabilization of the binding
pocket on oligomer receptors leads to displacement of
oligomers from neuronal surfaces and subsequent clear-
ance into the CSF. Furthermore, CSF concentrations of
fragments of the synaptic proteins neurogranin and syn-
aptotagmin were significantly decreased in CT1812-
treated versus placebo-treated patients, suggesting a
reduction in synaptic damage with drug treatment.
Because both TMEM97 and PGRMC1 are known to im-
pact lipid metabolism (Ahmed et al., 2012; Ebrahimi-
Fakhari et al., 2016; Riad et al., 2018), plasma samples
were analyzed for changes from baseline in a number of
metabolites. Preliminary findings suggest that 11 individu-
al metabolites that are known to be lowered in AD (Li et
al., 2016; Toledo et al., 2017) were significantly altered
from baseline in CT1812-treated versus placebo-treated
patients and that 10 of these were elevated with drug
treatment, consistent with a positive effect on disease
course. In particular, lipid metabolites such as long chain
polyunsaturated fatty acids as well as carnitines and acyl-
carnitines decrease in AD (Toledo et al., 2017), whereas
CT1812 treatment resulted in significant increases in
these metabolites compared with placebo.
Together, these clinical data provide encouraging evi-
dence of CT1812 target engagement in patients and are
consistent with preclinical reports demonstrating that
CT1812 and related S2R allosteric antagonists reduces
synaptic damage and modifies disease biomarkers. The
presented data are currently under peer review, and addi-
tional phase 2 six-month trials in this patient population
are underway.
The Role of the S2R Complex Protein
PGRMC1 in Health and Pathology
Because S2R/TMEM97 forms a complex with
PGRMC1, the value in pharmacologically targeting S2R
includes the effects exerted through possible alteration of
PGRMC1 activity, as well. The field of S2R research there-
fore includes understanding the role of PGRMC1 in health
and pathology.
To illustrate the vast potential of PGRMC1 to impact
heath and disease, Cahill and colleagues have worked to
characterize the role of PGRMC1 in cell biology and cellu-
lar metabolic regulation. Evolutionary studies suggest that
the PGRMC1 gene first originated in a bacterium and, fol-
lowing incorporation into eukaryotic cells, was involved in
sterol production, hypothetically to modulate early mito-
chondrial oxygen response. This was perhaps related to a
membrane trafficking motif and the ability to transfer ster-
ols to mitochondria (as demonstrated through preliminary,
unpublished findings). The eukaryotic PGRMC1-like fam-
ily was originally defined by the presence of a variable
number of residues inserted between two helices on the
protein surface (Mifsud and Bateman, 2002). This region
has high predicted propensity to form coiled-coil pro-
tein interactions and has recently been shown to share
similarity with motifs in certain myosins (components
of the actin cytoskeleton; Hehenberger et al., 2020).
Furthermore, PGRMC1 can be found in complexes with
components of the actin cytoskeleton (Salsano et al.,
2020; Thejer et al., 2020a). Taken together, these re-
sults suggest that PGRMC1 modulation of the actin cy-
toskeleton could regulate actin-mediated mechanical
forces required for vesicle trafficking. Modern PGRMC1
influences oxic/glycolytic and sterol metabolism, and
membrane trafficking, which have all been associated
with the s receptors (Nicholson et al., 2016; Cahill and
Medlock, 2017).
Evolutionary studies also revealed that the main
PGRMC1 tyrosine phosphorylation sites (Y139 and Y180)
appeared at the same time as the last eumetazoan com-
mon ancestor (LEUCA; common ancestor of cnidarians
and bilaterally symmetrical animals). This was the first
organism to possess a gastrulation organizer and post-
gastrulation differentiated cell types. Among these dif-
ferentiated cells that first appeared in emetazoans were
neurons (Hehenberger et al., 2020), suggesting an inti-
mate and perhaps master-regulating role between
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PGRMC1 activity and neurogenesis, and perhaps adult
neural state identity. Strikingly, one of the PGRMC1
phosphorylated tyrosines (Y139) is a coiled-coil heptad
repeat residue in the center of the coiled-coil myosin-
like motif (Hehenberger et al., 2020), suggesting imme-
diately that its phosphorylation at gastrulation could (1)
disrupt coiled-coil interactions, and (2) establish new
phospho-tyrosine-dependent interactions with different
proteins. This is striking because of the changes in
actin-cytoskeleton associated with early gastrulation
events (Patwari and Lee, 2008). In human cancer cells,
mutation of PGRMC1 phosphorylation sites leads to
changes in PI3K/Akt activity, glucose metabolism, epi-
genetic genomic CpG methylation, and mitochondrial
structure and function, leading to attenuated cancer
growth and alterations to signaling pathways associated
with pattern establishment and cell differentiation.
Results reported by Cahill at the symposium have since
been published (Thejer et al., 2020a,b). Perturbations in
glucose metabolism, epigenetics, and mitochondria are
all symptoms of AD (Cenini and Voos, 2019; Ehrlich,
2019; Esposito and Sherr, 2019). Notably, gastrulation
establishes the platform on which subsequent epige-
netic determination of animal tissue-specific differenti-
ated cell identity is based, and this may be related to
changes in PGRMC1 function regulated by phosphoryl-
ation. We note that the same effects could direct syn-
apse function.
It has long been known that a PGRMC1:deleted in colo-
rectal carcinoma (DCC) interaction directs early embry-
onic axon guidance of central nerve cord neurons form
nematodes to mammals (Cahill, 2007). We now know that
PGRMC1 continues to function in adult synapses and is
present in a protein complex that is the target of small
molecule CT1812 which attenuates AD symptoms (re-
ported here). We also know that DCC is critical in the
mechanism of long-term potentiation, with both presyn-
aptic and postsynaptic roles (Glasgow et al., 2018, 2020).
Therefore, one simple hypothesis to explain the mecha-
nism of action of CT1812 is that oligomeric Ab engages
the S2R/TMEM97/PGRMC1 complex in a state where
PGRMC1 cannot contribute to DCC function, thereby pre-
venting synaptic plasticity. This suggests an underappre-
ciated role for PGRMC1 in AD pathogenesis. Indeed, the
association of PGRMC1 with the complex that internalizes
both Ab and the genetic risk factor ApoE (Riad et al.,
2020), and the association of Tau trafficking with that
complex (Rodriguez-Vieitez and Nielsen, 2019; Yamazaki
et al., 2019), potentially associates PGRMC1 biology with
most of the main cell biological symptoms of AD (ApoE,
Tau, Ab , glycolysis, epigenetics, mitochondria, LTP), and
with the mechanism of action of CT1812. We are unaware
of another protein for which this claim can be made.
Furthermore, PGRMC1 plays an important role in media-
ting progesterone function and its associated neuroprotec-
tive effects. Nguyen et al., had previously reported that
the miRNA let7i, which negatively regulates PGRMC1 ex-
pression, is upregulated following ischemic injury such as
stroke (Nguyen et al., 2018). This results in a disruption
of progesterone-induced BDNF release, reducing
progesterone’s protective effect. Singh and colleagues
are investigating whether inhibiting let7i will facilitate
progesterone-mediated neuroprotection (Kim et al.,
2019). To this end, they have used an H2O2-induced
model of oxidative stress. At the SfN meeting and the
S2R satellite symposium, Singh presented preliminary
results from these studies that indicate an elevation in
let7i expression in both the C6 astrocyte and SH-SY5Y
neuronal cell lines, and a downregulation of PGRMC1,
following H2O2-induced oxidative stress. Addition of a
let7i inhibitor appears to reverse this negative effect and
to restore the progesterone-mediated protection against
oxidative stress in both cell types, as well as to enhance
the protective efficacy of progesterone in an animal
model of stroke (Nguyen et al., 2018). If further investiga-
tion confirms these findings, inhibitors of let7i may be an
adjunctive therapy for neural injury and neurodegenera-
tive disease. Given the relationship between PGRMC1
and S2R, the described influence of let7i may have rele-
vance to the modulating neurobiology of S2R in health
and disease.
Development of S2R Ligands
Further development of S2R ligands will facilitate re-
search into the receptor’s role in health and disease. Initial
high-affinity ligands allowed pharmacological characteri-
zation of S2R activity and led to the understanding that it
is present in many tumor types. Its ligands may also have
a cytotoxic effect. In combination with the S2R role in AD,
the therapeutic potential of ligands is significant and war-
rants their further development.
Abate and colleagues have employed a variety of ap-
proaches to generate these compounds and have pro-
duced fluorescent S2R ligands, nanoparticles that can be
used as tools in S2R research, and multi-target agents in-
tended to have cytotoxic effects (Abate et al., 2018,
2019). To accomplish these goals, the lead compounds
were decorated, in the appropriate position, with alkyl
linkers bridging the pharmacophore from either a fluores-
cent tag or a fluorescent nanoparticle as the quantum dot
(Abate et al., 2011, 2014; Niso et al., 2015; Pati et al.,
2018a). The resulting high-affinity fluorescent S2R agents
are useful for non-radioactive binding assays and visual-
ization of protein localization in living cells. In addition,
multifunctional compounds were developed by connect-
ing metal chelating moieties to S2R directing basic por-
tions using alkyl linkers (Pati et al., 2015, 2018b).
Initial studies using these novel ligands revealed that
S2R/TMEM97 binding is not needed for cytotoxic activity
but increases the specificity of delivery and reduces toxic
off-site activity. Together, these findings confirm that
S2Rs are versatile targets worthy of continued investiga-
tion, and that S2R ligands should be developed through
different strategies for use in diagnosis and treatment of
diseases from tumors to neurologic disorders.
Conclusions and Future Directions
S2R is involved in a number of biological processes rele-
vant to both health and disease. Understanding of S2R
pharmacology and biology has improved to a noteworthy
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degree in recent years, but a number of outstanding ques-
tions remain. Further research and compound develop-
ment are needed to ensure the full potential of this receptor
as a therapeutic target in cancer and neurodegeneration is
realized. The annual International Symposium on Sigma-2
Receptors at the SfN conference ensures that researchers
focused on this versatile receptor and its associated pro-
teins are sharing progress and collaboratively moving the
field forward.
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